Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines

Vaccine

Volumn 25, Issue 26, 2007, Pages 4949-4959

  Wan, Yanmin ^a   Wu, Lan ^a   Liu, Lianxing ^a,b,c   Xu, Jianqing ^a   Liu, Ying ^a   Liu, Yong ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Envelope; HIV 1; Immunogen design; Vaccine

Indexed keywords

GLYCOPROTEIN 145; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEUCINE; POLYLEUCINE; RECOMBINANT TIANTAN VACCINNIA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CODON; CONTROLLED STUDY; DNA IMMUNIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THAILAND; VIRUS ENVELOPE;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CODON; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HIV-1; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 34249745282     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.118     Document Type: Article

References (55)

1. Pitisuttithum P., Berman P.W., Phonrat B., Suntharasamai P., Raktham S., Srisuwanvilai L.O., et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J AIDS 37 (2004) 1160-1165
2. Desrosiers R.C. Prospects for an AIDS vaccine. Nat Med 10 (2004) 221-223
3. Gotch F.M., Imami N., and Hardy G. Candidate vaccines for immunotherapy in HIV. HIV Med 2 (2001) 260-265
4. Ross R.W., Wright M.E., and Tavel J.A. Ongoing trials of immunebased therapies for HIV infection in adults. Exp Opin Biol Ther 1 (2001) 413-424
5. Girard M., Habel A., and Chanel C. New prospects for the development of a vaccine against human immunodeficiency virus type 1: an overview. C R Acad Sci 322 (1999) 959-966 [III]
6. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Montefiori D.C., Altman J.D., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 76 12 (2002) 6138-6146
7. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74 2 (2000) 627-643
8. Kwong P.D., Wyatt R., Sattentau Q.J., Sodroski J., and Hendrickson W.A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 74 4 (2000) 1961-1972
9. Moore J.P., and Binley J. HIV Envelope's letters boxed into shape. Nature 393 6686 (1998) 630-631
10. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70 3 (1996) 1863-1872
11. Parren P.W., Moore J.P., Burton D.R., and Sattentau Q.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 Suppl. A (1999) S137-S162
12. Reitter J.N., Means R.E., and Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat Med 4 6 (1998) 679-684
13. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 6686 (1998) 705-711
14. McMichael A.J. HIV vaccine. Annu Rev Immunol 24 (2006) 227-255
15. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 76 11 (2002) 5357-5368
16. Gu S., Huang T., Miao Y.H., Zhao Y.H., Han C.H., Xiao Y., et al. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J 6 4 (1991) 241-243
17. Gu S., Tian-Min H., Li R., Yi-Hong M., Chi-Ming C., Hua L., et al. Immunogenicty in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Vaccine (1992) 349-355
18. Zhao K., et al. Arch TianTan Vaccinia Res (1975) 9 ISBN: R979
19. Ren L., Qiu C., Huang X., Pan X., Xu J., and Shao Y. Construction and immunogenecity analysis of HIV-1 B' gag-env DNA vaccine. Chin J Microbiol Immunol 26 7 (2006) 654-658
20. Cole K.S., Paliotti M.J., Murphey-Corb M., and Montelaro R.C. Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV. J Med Primatol 29 (2000) 220-230
21. Cole K.S., Rowles J.L., Jagerski B.A., Murphey-Corb M., Unangst T., Clements J.E., et al. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 71 7 (1997) 5069-5079
22. Letvin N.L., Barouch D.H., and Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20 (2002) 73-99
23. Mascola J.R. Defining the protective antibody response for HIV-1. Curr Mol Med 3 (2003) 209-216
24. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 76 12 (2002) 6138-6146
25. Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Seaman M.S., Beaudry K., et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78 14 (2004) 7490-7497
26. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.L., et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12 (1998) 2407-2415
27. Belshe R.B., Graham B.S., Keefer M.C., Gorse G.J., Wright P., Dolin R., et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 272 (1994) 475-480
28. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., Keefer M.C., et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group and the Correlates of HIV Immune Protection Group. J Infect Dis 177 (1998) 310-319
29. Mascola J.R., Snyder S.W., Weinslow O.S., Belay S.M., Belshe R.B., Scwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 173 (1996) 340-348
30. Matthews T.J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 10 (1994) 631-632
31. Beddows S., Lister S., Cheingsong R., Bruck C., and Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 73 (1999) 1740-1745
32. VanCott T.C., Bethke F.R., Burke D.S., Redfield R.R., and Birx D.L. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 155 (1995) 4100-4110
33. Evans L.A., Thomson-Honnebier G., Steimer K., Paoletti E., Perkus M.E., Hollander H., et al. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS 3 (1989) 273-276
34. Gnann J.W.J., Nelson J.A., and Oldstone M.B.A. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 61 (1987) 2639-2641
35. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79 14 (2005) 8812-8827
36. Bower J.F., Yang X., Sodroski J., and Ross T.M. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 78 9 (2004) 4710-4719
37. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., et al. Stabilization of the soluble,cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76 17 (2002) 8875-8889
38. Yang X., Farzan M., Wyatt R., and Sodroski J. Characterization of stable, soluble trimer containing complete ectodomains of HIV-1 envelope glycoprotein. J Virol 74 12 (2000) 5716-5725
39. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76 9 (2002) 4634-4642
40. Bower J.F., Li Y.X., Wyatt R., and Ross T.M. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 24 (2006) 5442-5451
41. Earl P., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75 2 (2001) 645-653
42. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 (1996) 1100-1108
43. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., and Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69 (1995) 5723-5733
44. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., and Robinson J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 67 (1993) 4557-4565
45. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., and Wyatt R. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71 (1997) 9808-9812
46. Kim Y.B., Han D.P., Cao C., and Cho M.W. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305 (2002) 124-137
47. Yang Z., Chakrabarti B.K., Xu L., Welcher B., Kong W.P., Leung K., et al. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol 78 8 (2004) 4029-4036
48. Stamatatos L., and Cheng-Mayer C. An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J Virol 72 (1998) 7840-7845
49. Gzyl J., Bolesta E., Wierzbicki A., Kmieciak D., Naito T., Honda M., et al. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 318 2 (2004) 493-506
50. Nguyen M., Pean P., Lopalco L., Nouhin J., Phoung V., Ly N., et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 42 4 (2006) 412-419
51. Xu J.Q., Ren L., Huang X.G., Qiu C., Liu Y., Liu Y., et al. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS 20 (2006) 2293-2303
52. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIVgp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 659-684
53. Conley A.J., Gorny M.K., Kessler II J.A., Boots L.J., Ossorio-Castro M., Koenig S., et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 68 (1994) 6994-7000
54. Bartholdy C., Christensen J.P., Wodarz D., and Thomsen A.R. Persistent virus infection despite chronic cytotoxic T-lymphocyte activation in gamma interferon-deficient mice infected with lymphocytic choriomeningitis virus. J Virol 74 (2000) 10304-10311
55. Belz G.T., Xie W., and Doherty P.C. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8 + T cell responses. J Immunol 166 (2001) 4627-4633